- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | FDA cracks down on online black market for weight loss peptides | ||
| Mi | Roche licenses Simcere's B-cell-targeting tri-specific for $1.53bn | ||
| Mi | Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology | ||
| Mi | Takeda and Weave Bio collaborate on AI-driven automation in drug development | ||
| Di | Trump lines up MFN deals with nine mid-size pharmas on drug pricing push | ||
| Di | Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal | ||
| Di | PharmaEssentia's Besremi receives FDA approval for ET | ||
| Di | Kazia closes oversubscribed offering to fund paxalisib's clinical development | ||
| Mo | ESC 2026: Statins show worth despite emergence of PCSK9 inhibitors | ||
| Mo | Teva Pharmaceuticals to acquire BioXcel assets for up to $125m | ||
| Fr | Lilly's Mounjaro wins US label expansion for cardiovascular risk reduction | ||
| Fr | FDA approves Priovant's rare autoimmune therapy Lisraya in indication first | ||
| Fr | AusperBio raises $120m to progress hepatitis B therapies | ||
| Fr | FDA to review Kowa Pharmaceuticals' NDA for glaucoma eye drop K-911 | ||
| 27.08. | SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race | ||
| 27.08. | ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients | ||
| 27.08. | FDA grants RPDD to ReviR's RTX-117 for CMT | ||
| 27.08. | ViiV Healthcare's Tivicay PD gains FDA approval for paediatric HIV therapy | ||
| 26.08. | RevMed's pancreatic cancer drug breezes through with swift approval | ||
| 26.08. | Metsera backers establish new biotech armed with China-licensed immunology asset | ||
| 26.08. | Jazz secures FDA approval for Ziihera in advanced HER2+ GEA | ||
| 26.08. | ESC 2026: Common pharma excipient linked to uptick in cardiovascular risk | ||
| 26.08. | McKesson to acquire Precision Medicine Group for $2.25bn | ||
| 25.08. | J&J's Imaavy secures expanded US approval in rare blood disorder | ||
| 25.08. | FDA places clinical hold on Regenxbio's RGX-121 in MPS II trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.